Multiple Myeloma

Philadelphia oncology leaders tackle gaps in biomarker testing, breast cancer advances, myeloma innovation, and clinical trial equity.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how to optimally treat this adverse effect.

Lalan Wilfong, MD, a medical oncologist well known for his work in practice transformation, said he looks forward to creating "something more or less from scratch."

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.

The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies, says Nick Richardson, DO, MPH.

The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

Beyond progression-free survival, the combination of teclistamab and daratumumab hyaluronidase-fihj showed deep clinical responses, notes Ajay K. Nooka, MD, MPH.

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Ajai Chari, MD, discusses how the results of the MajesTEC-3 trial may translate to a real-world second-line population with multiple myeloma.

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Teclistamab had received an accelerated approval in October 2022; the combination regimen is administered subcutaneously.

Peter Voorhees, MD, explains how new daratumumab data shift smoldering multiple myeloma from watchful waiting to treatment.

Treatment for multiple myeloma often confers a higher risk of subsequent cardiovascular disease, but the impact of medications for the latter in this setting is not fully understood.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.